AskBio Inc
Clinical trials sponsored by AskBio Inc, explained in plain language.
A gene therapy company, subsidiary of Bayer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy injection aims to repair failing hearts Results expected Oct 2026 (estimated)
-
Gene therapy trial offers hope for rare muscle disease
Disease control OngoingThis study tests a single dose of a gene therapy called AB-1003 in 10 adults with a rare genetic muscle disease (LGMD2I/R9). The goal is to see if it is safe and can help improve muscle function. Participants must be able to walk or run 10 meters in under 30 seconds.
Phase 1/2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Gene therapy injection aims to repair failing hearts
Disease control OngoingThis study tests a one-time gene therapy called AB-1002, given directly into the heart arteries, for people with advanced heart failure (NYHA Class III). The goal is to see if it can improve heart function, reduce symptoms, and lower the risk of death or hospitalization. About 15…
Phase 2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Gene therapy AB-1005: how safe is it years later?
Knowledge-focused By invitation onlyThis study follows 132 people with Parkinson's disease or multiple system atrophy who previously received the gene therapy AB-1005. Researchers will track safety and how well the treatment works over the long term. No new treatments are given; it's purely observational.
Sponsor: AskBio Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC